PAR 2.17% 23.5¢ paradigm biopharmaceuticals limited..

Ann: Phase 2 Synovial Fluid Biomarker Study Update, page-7

  1. 1,608 Posts.
    lightbulb Created with Sketch. 170
    I am notoriously a glass half empty sort of bloke,
    but to me this is excellent news for the long
    term. A much larger trial allowing for much
    more weighty evidence for applications to
    TGA and FDA.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.